Jennifer Madonia
Overview
Explore the profile of Jennifer Madonia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhardwaj R, Malatesta J, Madonia J, Anderson M, Morris B, Matschke K, et al.
Clin Transl Sci
. 2024 Nov;
17(12):e70048.
PMID: 39602316
Zavegepant is a calcitonin gene-related peptide receptor antagonist for acute migraine treatment. This Phase I, open-label, fixed-sequence study evaluated the effects of itraconazole (a strong cytochrome P450 3A4 [CYP3A4] and...
2.
Bertz R, Collins J, Madonia J, Bhardwaj R, Kamen L, Matschke K, et al.
Headache
. 2024 Nov;
65(3):484-494.
PMID: 39508426
Objective: To compare the rate and extent of absorption of zavegepant 10 mg (therapeutic dose) or 20 mg (supratherapeutic dose) nasal spray during a migraine attack versus non-migraine period, assess...
3.
Bhardwaj R, Collins J, Madonia J, Matschke K, Bertz R, Liu J
Headache
. 2024 Nov;
65(1):14-23.
PMID: 39501702
Objective: The potential for drug-drug interaction of multiple-dose intranasal zavegepant on the single-dose oral contraceptive ethinyl estradiol and levonorgestrel (EE-LNG) was evaluated. Background: Zavegepant (as a nasal spray) is a...
4.
Bhardwaj R, Donohue M, Madonia J, Matschke K, Anderson M, Morris B, et al.
Headache
. 2024 Oct;
65(2):315-325.
PMID: 39364589
Objective: To evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) interactions between zavegepant and sumatriptan in healthy adults. Background: Zavegepant is a high-affinity, selective, small-molecule calcitonin gene-related peptide receptor antagonist administered...
5.
Bhardwaj R, Donohue M, Madonia J, Anderson M, Matschke K, Bertz R, et al.
Clin Transl Sci
. 2024 Sep;
17(10):e70015.
PMID: 39348235
Zavegepant, a high-affinity, selective, small-molecule calcitonin gene-related peptide receptor antagonist, is approved as a nasal spray for acute treatment of migraine in adults. This phase I, open-label, single-center, single-period, nonrandomized...
6.
Mullin K, Croop R, Mosher L, Fullerton T, Madonia J, Lipton R
Cephalalgia
. 2024 Aug;
44(8):3331024241259456.
PMID: 39210835
Background: Zavegepant is the first small molecule calcitonin gene-related peptide receptor antagonist for intranasal administration for the acute treatment of migraine. The objective of this study was to evaluate the...
7.
Bhardwaj R, Donohue M, Madonia J, Morris B, Marbury T, Matschke K, et al.
Clin Transl Sci
. 2024 Jul;
17(7):e13813.
PMID: 39014555
Zavegepant, a high-affinity, selective, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, is approved in the United States for acute treatment of migraine in adults. The effects of moderate hepatic impairment...
8.
Hughes J, Bertz R, Bhardwaj R, Donohue M, Madonia J, Anderson M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 May;
13(6):1044-1054.
PMID: 38812357
Zavegepant is a novel gepant administered as a nasal spray approved in the United States at a 10 mg dose for the acute treatment of migraine with or without aura...
9.
Lipton R, Croop R, Stock D, Madonia J, Forshaw M, Lovegren M, et al.
Lancet Neurol
. 2023 Feb;
22(3):209-217.
PMID: 36804093
Background: Intranasal formulations can provide treatment options for people with migraine in whom oral drugs are ineffective, slow-acting, or intolerable because of nausea and vomiting. Zavegepant, an intranasally administered small...
10.
Croop R, Madonia J, Stock D, Thiry A, Forshaw M, Murphy A, et al.
Headache
. 2022 Oct;
62(9):1153-1163.
PMID: 36239038
Objective: Evaluate the efficacy, safety, and tolerability of zavegepant nasal spray in the acute treatment of migraine. Background: Calcitonin gene-related peptide-targeting agents are a novel class of therapeutics for migraine,...